EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension

David R Lynch iD, Melanie P Chin, Sylvia Boesch, Martin B Delatycki, Paola Giunti, Angie Goldsberry, J Chad Hoyle, Caterina Mariotti iD, Katherine D Mathews, Wolfgang Nachbauer, Megan O'Grady, Susan Perlman und 4 weitere

Movement Disorders · 2023-02 · 38 (2) · 313-320

DOI: 10.1002/mds.29286 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 29.11.2022. Verfasst von David R Lynch und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Friedreich Ataxia, Triterpenes. Die Arbeit wurde bisher 134-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

MOXIe was a two‐part study evaluating the safety and efficacy of omaveloxolone in patients with Friedreich's ataxia, a rare, progressive neurological disease with no proven therapy. MOXIe part 2, a randomized double‐blind placebo‐controlled trial, showed omaveloxolone significantly improved modified Friedreich's Ataxia Rating Scale (mFARS) scores relative to placebo. Patients who completed part 1 or 2 were eligible to receive omaveloxolone in an open‐label extension study.

Objective

The delayed‐start study compared mFARS scores at the end of MOXIe part 2 with those at 72 weeks in the open‐label extension period (up to 144 weeks) for patients initially randomized to omaveloxolone versus those initially randomized to placebo.

Methods

We performed a noninferiority test to compare the difference between treatment groups (placebo to omaveloxolone versus omaveloxolone to omaveloxolone) using a single mixed model repeated measures (MMRM) model. In addition, slopes of the change in mFARS scores were compared between both groups in the open‐label extension.

Results

The noninferiority testing demonstrated that the difference in mFARS between omaveloxolone and placebo observed at the end of placebo‐controlled MOXIe part 2 (−2.17 ± 1.09 points) was preserved after 72 weeks in the extension (−2.91 ± 1.44 points). In addition, patients previously randomized to omaveloxolone in MOXIe part 2 continued to show no worsening in mFARS relative to their extension baseline through 144 weeks.

Conclusions

These results support the positive results of MOXIe part 2 and indicate a persistent benefit of omaveloxolone treatment on disease course in Friedreich's ataxia. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Friedreich AtaxiaTriterpenesHumansDouble-Blind MethodDisease Progression

Substanzen

omaveloxoloneTriterpenes

Autor:innen und Institutionen

  • Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Reata Pharmaceuticals, Dallas, Texas, USA.
  • Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
  • Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • University College London Hospital, London, United Kingdom.
  • Department of Neurology, Ohio State University College of Medicine, Columbus, Ohio, USA.

ORCID-Profile: David R Lynch, Caterina Mariotti

Zitieren

APA

Lynch, D. R., Chin, M. P., Boesch, S., Delatycki, M. B., Giunti, P., Goldsberry, A., Hoyle, J. C., Mariotti, C., Mathews, K. D., Nachbauer, W., O'Grady, M., Perlman, S., Subramony, S. H., Wilmot, G., Zesiewicz, T., & Meyer, C. J. (2023). Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension. Movement Disorders, 38(2), 313-320. https://doi.org/10.1002/mds.29286

Vancouver

Lynch DR, Chin MP, Boesch S, Delatycki MB, Giunti P, Goldsberry A, et al. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension. Movement Disorders. 2023;38(2):313-320. doi:10.1002/mds.29286

BibTeX
@article{Lynch2023,
  author = {Lynch, David R and Chin, Melanie P and Boesch, Sylvia and Delatycki, Martin B and Giunti, Paola and Goldsberry, Angie and Hoyle, J Chad and Mariotti, Caterina and Mathews, Katherine D and Nachbauer, Wolfgang and O'Grady, Megan and Perlman, Susan and Subramony, S H and Wilmot, George and Zesiewicz, Theresa and Meyer, Colin J},
  title = {Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension},
  journal = {Movement Disorders},
  year = {2023},
  volume = {38},
  number = {2},
  pages = {313--320},
  doi = {10.1002/mds.29286}
}
Kostenlos starten →